BioScrip, Inc. (NASDAQ:BIOS) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.
Other research analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research report on Wednesday, July 5th. SunTrust Banks, Inc. raised shares of BioScrip from a “hold” rating to a “buy” rating and upped their target price for the company from $3.25 to $3.75 in a report on Thursday, August 10th. Jefferies Group LLC reaffirmed a “buy” rating and set a $4.00 target price (up from $3.00) on shares of BioScrip in a report on Thursday, August 10th. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Finally, Barrington Research upped their target price on shares of BioScrip to $3.50 and gave the company an “outperform” rating in a report on Monday, June 26th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $3.75.
Shares of BioScrip (NASDAQ BIOS) opened at 3.09 on Thursday. The stock’s 50 day moving average is $2.88 and its 200 day moving average is $2.09. BioScrip has a 52 week low of $0.98 and a 52 week high of $3.43. The stock’s market cap is $393.90 million.
BioScrip (NASDAQ:BIOS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.01. The company had revenue of $218.11 million for the quarter, compared to the consensus estimate of $220.05 million. The firm’s revenue for the quarter was down 6.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.14) EPS. On average, equities analysts forecast that BioScrip will post ($0.55) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://stocknewstimes.com/2017/08/19/bidaskclub-downgrades-bioscrip-inc-bios-to-hold.html.
In other news, Director Coliseum Capital Management, L sold 886,478 shares of the stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $3.08, for a total value of $2,730,352.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.30% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. State Street Corp boosted its stake in shares of BioScrip by 10.6% in the fourth quarter. State Street Corp now owns 1,456,697 shares of the company’s stock worth $1,515,000 after buying an additional 139,110 shares during the period. Teachers Advisors LLC boosted its stake in shares of BioScrip by 14.0% in the fourth quarter. Teachers Advisors LLC now owns 162,778 shares of the company’s stock worth $169,000 after buying an additional 20,000 shares during the period. Perkins Capital Management Inc. boosted its stake in shares of BioScrip by 4.2% in the first quarter. Perkins Capital Management Inc. now owns 310,500 shares of the company’s stock worth $528,000 after buying an additional 12,500 shares during the period. Roanoke Asset Management Corp NY boosted its stake in shares of BioScrip by 2.6% in the first quarter. Roanoke Asset Management Corp NY now owns 233,280 shares of the company’s stock worth $397,000 after buying an additional 6,000 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of BioScrip by 1.1% in the first quarter. Wells Fargo & Company MN now owns 113,710 shares of the company’s stock worth $193,000 after buying an additional 1,254 shares during the period. 85.62% of the stock is owned by hedge funds and other institutional investors.
About BioScrip
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
